OPKO Health, Inc. announced today that its GeneDx subsidiary and
business unit has been selected to give 11 platform talks and 18 poster
presentations on a range of genetics-related topics at the 2016 American
College of Medical Genetics and Genomics (ACMG) Annual Meeting. These
presentations support GeneDx's position as an industry leader in the
wider genomics industry.
Marc Grodman MD, CEO of BioReference/GeneDX states, "We are honored to
have such a large number of presentations accepted at this year's ACMG
meeting and believe the depth and scope of our contributions demonstrate
not only our commitment in expanding the scope of our genomic testing
but also a meaningful contribution to enrich the scientific community at
This year's presentations cover a range of topics ranging from inherited
cancer testing to whole exome sequencing. Some of GeneDx's featured
presentations at the meeting include:
GeneDx's experience from the first 100 XomeDxXpress cases
performed for patients in critical care including diagnostic yield and
how the results impacted medical management;
The potential use of Whole Exome Sequencing for fetal anomalies and
The detection of mosaic variants in genes causing germline
neurodevelopmental disorders, such as epilepsy;
Multiple talks describing genes that have recently been associated
with neurodevelopmental delay, either as a new gene-disease
association or as an expansion of a previously described clinical
For a complete list of GeneDx's platform presentations and posters,
please visit the GeneDx website http://www.genedx.com/acmg2016/
or stop by and visit booth #413 at the 2016 ACMG conference to learn
Over the last several years, GeneDx has been striving to better
understand the genetic causes of autism and intellectual disability
through research and its robust Whole Exome Sequencing program, perhaps
best demonstrated by several of the company's presentations at this
year's ACMG annual meeting. Based on this increased understanding and
knowledge, GeneDx is proud to announce the launch of its Autism/Intellectual
Disability (ID) Xpanded Panel. This is a dynamic testing panel
analyzing approximately 2,000 genes that have been associated with
autism, intellectual disability and/or developmental delay.
To learn more about GeneDx's complete list of testing options, please
or email firstname.lastname@example.org.
About OPKO Health, Inc.:
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes Bio-Reference Laboratories, the
nation's third-largest clinical laboratory with a core genetic testing
business and a 420-person sales force to drive growth and leverage new
products, including the 4Kscore® prostate cancer test and the Claros®1
in-office immunoassay platform. Our pharmaceutical business features
Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency (March 29, 2016 PDUFA date) and VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation launched by
partner Tesaro, IV formulation in Phase 3). Our biologics business
includes hGH-CTP, a once-weekly human growth hormone injection (in Phase
3 and partnered with Pfizer), and a long-acting Factor VIIa drug for
hemophilia (entering Phase 2a). We also have production and distribution
assets worldwide, multiple strategic investments and an active business
development strategy. More information is available at www.opko.com.
GeneDx is a world leader in Genomics with an acknowledged expertise
in rare and ultra rare genetic disorders, as well as one of the broadest
menus of sequencing services available among commercial laboratories.
GeneDx provides testing to patients and their families in more than
55 countries. To learn more, please visit www.genedx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160302005766/en/
OPKO Health, Inc.
Carly Erickson, 202-600-4558
Terry Rooney, 212-223-0689
Source: OPKO Health, Inc.
News Provided by Acquire Media